Published in Ann Rheum Dis on May 05, 2005
Role of CTHRC1 in Diagnosis of Rheumatoid Arthritis | NCT04092244
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis (2006) 2.68
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol (2010) 1.94
Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther (2008) 1.61
Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum (2009) 1.56
Analyses of differential proteome of human synovial fibroblasts obtained from arthritis. Clin Rheumatol (2008) 1.56
Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol (2006) 1.54
Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2006) 1.34
The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther (2008) 1.30
Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther (2009) 1.20
Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther (2008) 1.16
Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM (2009) 1.13
Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther (2012) 1.13
Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res Ther (2006) 1.12
Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol (2014) 1.10
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis (2014) 1.05
A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis (2011) 1.05
Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum (2007) 1.04
Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int (2009) 1.02
Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis (2008) 1.02
Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther (2011) 1.01
Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatol Int (2010) 0.93
A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol (2007) 0.90
Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes? Arthritis Res Ther (2011) 0.88
Rheumatoid factors: clinical applications. Dis Markers (2013) 0.87
Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope. Ann Rheum Dis (2006) 0.86
Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. RMD Open (2016) 0.85
Efficacy of leflunomide addition in relation to prognostic factors for patients with active early rheumatoid arthritis failing to methotrexate in daily practice. Clin Rheumatol (2011) 0.83
Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients. Korean J Intern Med (2010) 0.83
[Early rheumatoid arthritis--rapid help is double help]. Z Rheumatol (2007) 0.81
Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. Arthritis Res Ther (2015) 0.81
Serum IgG activity against cyclic citrullinated peptide in patients evaluated for rheumatoid factor correlates with the IgM isotype. Rheumatol Int (2008) 0.80
The diagnostic utility of the anti-CCP antibody test is no better than rheumatoid factor in South Africans with early rheumatoid arthritis. Clin Rheumatol (2010) 0.80
Diagnostic value of anti-cyclic citrullinated peptide antibody for rheumatoid arthritis in a Chinese population: a meta-analysis. Rheumatol Int (2011) 0.80
[Autoantibody profile in rheumatoid arthritis]. Z Rheumatol (2007) 0.79
Are anti-citrulline autoantibodies better serum markers for rheumatoid arthritis than rheumatoid factor in Thai population? Rheumatol Int (2009) 0.78
Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open (2016) 0.78
Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Res Ther (2015) 0.78
Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display. Arthritis Res Ther (2015) 0.78
Anti-hnRNP B1 (RA33) autoantibodies are associated with the clinical phenotype in Russian patients with rheumatoid arthritis and systemic sclerosis. J Immunol Res (2014) 0.78
Determination of specificity and sensitivity of anti-RA 33 in diagnosis of early rheumatoid arthritis. Glob J Health Sci (2014) 0.77
Therapeutic effects of lactosyl derivative Gu-4 in a collagen-induced arthritis rat model. Glycoconj J (2012) 0.76
Annexin A2 as a target endothelial cell membrane autoantigen in Behçet's disease. Sci Rep (2015) 0.76
Physical Characteristics of a Citrullinated Pro-Filaggrin Epitope Recognized by Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Sera. PLoS One (2016) 0.75
Enhanced neutrophil phagocytic capacity in rheumatoid arthritis related to the autoantibodies rheumatoid factor and anti-cyclic citrullinated peptides. BMC Musculoskelet Disord (2015) 0.75
Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD Open (2017) 0.75
Urinary interleukin-6 as a predictor of radiographic progression in rheumatoid arthritis: A 3-year evaluation. Sci Rep (2016) 0.75
Identification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritis. Exp Mol Med (2016) 0.75
HnRNP A1 is Involved in Deep Vein Thrombosis Patients with Behçet's Disease. EBioMedicine (2016) 0.75
Aspects of early arthritis. Traditional DMARD therapy: is it sufficient? Arthritis Res Ther (2006) 0.75
The contribution of four immunogenetic markers for predicting persistent activity in patients with recent-onset rheumatoid arthritis or undifferentiated arthritis. ISRN Rheumatol (2011) 0.75
Correlation of Demographic and Clinical Characteristics with Rheumatoid Factor Seropositivity in Rheumatoid Arthritis Patients. Malays J Med Sci (2016) 0.75
Patterns and predictors of joint damage as assessed by the rheumatoid arthritis articular damage (RAAD) score in South Africans with established rheumatoid arthritis. Clin Rheumatol (2013) 0.75
Personalized medicine in rheumatology: the paradigm of serum autoantibodies. Auto Immun Highlights (2017) 0.75
A comparative study on the diversity of clinical features between the sero-negative and sero-positive rheumatoid arthritis patients. Rheumatol Int (2011) 0.75
[Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)]. Wien Klin Wochenschr (2008) 0.75
Anti-citrullinated protein antibody positive rheumatoid arthritis is primarily determined by rheumatoid factor titre and the shared epitope rather than smoking per se. PLoS One (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem (1993) 27.24
Analysis of serial measurements in medical research. BMJ (1990) 16.69
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum (2003) 10.65
Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) (1977) 9.55
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet (2004) 7.90
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest (1998) 6.92
Therapeutic strategies for rheumatoid arthritis. N Engl J Med (2004) 5.51
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet (1999) 4.98
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) (2004) 4.56
The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med (1996) 3.75
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis (2003) 3.33
Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis (2004) 3.23
Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol (2002) 2.97
Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet (1987) 2.81
Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis (2004) 2.71
Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther (2004) 2.58
Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol (2002) 2.42
The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest (1995) 2.37
Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol (2005) 2.28
Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis (2002) 1.75
The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol (1998) 1.63
Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis (2005) 1.57
Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol (1993) 1.46
Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum (1999) 1.42
Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol (2004) 1.35
Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis (2004) 1.29
Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res (2002) 1.22
Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol (2004) 1.21
Cases of early inflammatory polyarthritis should not be classified as having rheumatoid arthritis. J Rheumatol (2003) 1.20
Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2005) 1.19
Early arthritis therapy: rationale and current approach. J Rheumatol Suppl (1998) 1.03
Why do general practitioners request rheumatoid factor? A study of symptoms, requesting patterns and patient outcome. Ann Clin Biochem (2003) 0.95
The work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT) Br J Rheumatol (1992) 0.95
Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol (2002) 0.95
Anti-RA 33 as a marker antibody of rheumatoid arthritis in a Finnish population. Clin Exp Rheumatol (1994) 0.89
Using the Larsen index to assess radiographic progression in rheumatoid arthritis. J Rheumatol (2000) 0.88
The Austrian Early Arthritis Registry. Clin Exp Rheumatol (2004) 0.85
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Peripheral Nerves in Chronic Atrophic Arthritis. Am J Pathol (1942) 5.21
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Lesions of Skeletal Muscles in Rheumatoid Arthritis: Nodular Polymyositis. Am J Pathol (1946) 4.86
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) (2004) 4.56
Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis (2001) 4.18
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med (1978) 2.92
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
NODULAR POLYMYOSITIS IN RHEUMATOID ARTHRITIS. Science (1945) 2.59
Mixed connective tissue disease: to be or not to be? Arthritis Rheum (1998) 2.58
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) (2006) 2.36
Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest (1995) 2.33
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Identification of a site on 23S ribosomal RNA located at the peptidyl transferase center. Proc Natl Acad Sci U S A (1984) 2.22
A simulation study comparing properties of heterogeneity measures in meta-analyses. Stat Med (2006) 1.98
Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum (1995) 1.93
Long-term followup of uncemented tumor endoprostheses for the lower extremity. Clin Orthop Relat Res (2001) 1.93
Assessing remission in clinical practice. Rheumatology (Oxford) (2007) 1.92
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes (1993) 1.78
Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol (1991) 1.78
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis (2001) 1.78
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis (2006) 1.77
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
The reliability of analysis of intraoperative frozen sections for identifying active infection during revision hip or knee arthroplasty. J Bone Joint Surg Am (1996) 1.77
Quantitative ultrasound of the tibia depends on both cortical density and thickness. Osteoporos Int (2001) 1.76
Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis (2002) 1.75
Interobserver reliability of rheumatologists performing musculoskeletal ultrasonography: results from a EULAR "Train the trainers" course. Ann Rheum Dis (2005) 1.73
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) (2002) 1.69
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.67
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J (2010) 1.65
Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol (1997) 1.65
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol (2004) 1.65
Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. Arthritis Rheum (1992) 1.61
Fine specificity of anti-Ro(SSA) autoantibodies and clinical manifestations in patients with systemic lupus erythematosus. J Rheumatol (1996) 1.61
Quantitative immunohistochemistry of factor VIII-related antigen in breast carcinoma: a comparison of computer-assisted image analysis with established counting methods. Am J Clin Pathol (1996) 1.60
Concurrence of sarcoidosis and aortitis: case report and review of the literature. Ann Rheum Dis (2000) 1.57
Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol (1997) 1.53
Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum (1989) 1.48
Thy-1+ dendritic epidermal cells express T3 antigen and the T-cell receptor gamma chain. Proc Natl Acad Sci U S A (1987) 1.48
Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol (1990) 1.47
Calcitonin concentrations in patients with chronic kidney disease and medullary thyroid carcinoma or c-cell hyperplasia. Kidney Int (2006) 1.47
Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Correlation with clinical features. Am J Med (1982) 1.46
Neuropathological biomarker candidates in brain tumors: key issues for translational efficiency. Clin Neuropathol (2009) 1.46
Thy-1+ dendritic epidermal cells belong to the T-cell lineage. Proc Natl Acad Sci U S A (1987) 1.46
Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) (2008) 1.46
Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum (2009) 1.46
Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.45
Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus. J Rheumatol (1994) 1.44
Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol (1996) 1.42
A long-term review of the treatment of patients with Ewing's sarcoma in one institution. Eur J Surg Oncol (2001) 1.42
Antinuclear antibodies in patients with chronic idiopathic autoimmune thrombocytopenia followed 2-30 years. Am J Hematol (1989) 1.42
Rheumatoid arthritis and B lymphocyte alloantigen HLA-DRw4. J Rheumatol (1980) 1.41
Autoimmune reactions in patients with silicone breast implants. Wien Klin Wochenschr (1996) 1.39
Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.38
Plasma high-density lipoproteins and ischemic heart disease: studies in a large kindred with familial hypercholesterolemia. Ann Intern Med (1978) 1.38
Responder cells in the human autologous mixed lymphocyte reaction. J Clin Invest (1981) 1.37
Improved prediction of intraocular lens power using partial coherence interferometry. J Cataract Refract Surg (2001) 1.37
Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest (1999) 1.35
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
Human lymphocytes with either the OKT4 or OKT8 phenotype produce interleukin 2 in culture. J Clin Invest (1982) 1.33
Interaction of fibronectin with C1q and its collagen-like fragment (CLF). FEBS Lett (1981) 1.33